{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T22:37:10Z","timestamp":1769207830967,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T00:00:00Z","timestamp":1592784000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T00:00:00Z","timestamp":1592784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Vessels"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Myocardial injury is a problem associated with percutaneous coronary intervention (PCI). This study aimed to clarify the role of nicorandil administration in preventing myocardial injury. This study included patients with stable angina who underwent PCI from November 2013 to June 2016. Of 58 consecutive patients, the first 20 patients received only saline infusion after PCI (control group); the other 38 patients received a continuous intravenous infusion of nicorandil and saline after PCI (nicorandil group). Troponin I and brain natriuretic peptide (BNP) levels were measured. Vascular parameters, such as blood pressure (BP), cardiac output, cardio-ankle vascular index (CAVI), and estimated systemic vascular resistance (eSVR), were measured. Troponin I of both groups increased 12\u00a0h after PCI. Changes in BNP levels between immediately after PCI and 12\u00a0h after PCI were significantly higher in the control than in the nicorandil group (10.8\u2009\u00b1\u200944.2 vs.\u2009\u2212\u20092.6\u2009\u00b1\u200914.6\u00a0pg\/ml, <jats:italic>p<\/jats:italic>\u2009=\u20090.04). In the nicorandil group, BP, eSVR, and CAVI decreased significantly at 12\u00a0h after PCI compared with those immediately after PCI (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), whereas no change was observed in the control group. In a single linear analysis, the change in BP (<jats:italic>r<\/jats:italic>\u2009=\u20090.36, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01) and nicorandil administration (<jats:italic>r<\/jats:italic>\u2009=\u2009\u2212\u00a00.47, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) was significantly correlated with the change in CAVI, multiple regression analysis revealed that the changes in CO and eSVR were significant contributing factors for the changes in CAVI. PCI could result in myocardial injury and\/or cardiac burden in patients with stable angina. Nicorandil administration after PCI may be effective in relieving the burden by decreasing arterial stiffness (CAVI).<\/jats:p>","DOI":"10.1007\/s00380-020-01650-9","type":"journal-article","created":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T20:03:49Z","timestamp":1592856229000},"page":"1664-1671","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effect of nicorandil administration on cardiac burden and cardio-ankle vascular index after coronary intervention"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6386-8670","authenticated-orcid":false,"given":"Shuji","family":"Sato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mao","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Mikamo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayo","family":"Kawazoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuo","family":"Iizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahito","family":"Noro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohji","family":"Shirai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,22]]},"reference":[{"key":"1650_CR1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0140-6736(78)90500-7","volume":"1","author":"A Gr\u00fcntzig","year":"1978","unstructured":"Gr\u00fcntzig A (1978) Transluminal dilatation of coronary artery stenosis. Lancet 1:263","journal-title":"Lancet"},{"key":"1650_CR2","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.jcin.2013.07.009","volume":"6","author":"H Gada","year":"2013","unstructured":"Gada H, Kirtane AJ, Newman W, Hermiller JB, Mahaffey KW, Cutlip DE, Sudhir K, Hou L, Koo K, Stone GW (2013) 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III Trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions). JACC Cardiovasc Interv 6:1263\u20131266","journal-title":"JACC Cardiovasc Interv"},{"key":"1650_CR3","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.jacc.2015.11.051","volume":"67","author":"LO Jensen","year":"2016","unstructured":"Jensen LO, Thayssen P, Christiansen EH, Maeng M, Ravkilde J, Hansen KN, Hansen HS, Krusell L, Kaltoft A, Tilsted HH, Berencsi K, Junker A, Lassen JF, SORTOUTIV Investigators (2016) Safety and efficacy of everolimus-versus sirolimus-eluting stents: 5-year results from SORT OUT IV. J Am Coll Cardiol 67:751\u2013762","journal-title":"J Am Coll Cardiol"},{"key":"1650_CR4","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","volume":"339","author":"MB Leon","year":"1998","unstructured":"Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz RE (1998) A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 339:1665\u20131671","journal-title":"N Engl J Med"},{"issue":"1503","key":"1650_CR5","first-page":"1516","volume":"356","author":"WE Boden","year":"2007","unstructured":"Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS, COURAGE Trial Research Group (2007) Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356(1503):1516","journal-title":"N Engl J Med"},{"key":"1650_CR6","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1161\/CIRCULATIONAHA.114.013042","volume":"131","author":"J Iqbal","year":"2015","unstructured":"Iqbal J, Zhang YJ, Holmes DR, Morice MC, Mack MJ, Kappetein AP, Feldman T, Stahle E, Escaned J, Banning AP, Gunn JP, Colombo A, Steyerberg EW, Mohr FW, Serruys PW (2015) Optimal medical therapy improves clinical outcomes in patients undergoing revascularization with percutaneous coronary intervention or coronary artery bypass grafting: insights from the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial at the 5-year follow-up. Circulation 131:1269\u20131277","journal-title":"Circulation"},{"key":"1650_CR7","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1056\/NEJMoa1610227","volume":"375","author":"GW Stone","year":"2016","unstructured":"Stone GW, Sabik JF, Serruys PW, Simonton CA, G\u00e9n\u00e9reux P, Puskas J, Kandzari DE, Morice MC, Lembo N, Brown WM 3rd, Taggart DP, Banning A, Merkely B, Horkay F, Boonstra PW, van Boven AJ, Ungi I, Bog\u00e1ts G, Mansour S, Noiseux N, Sabat\u00e9 M, Pomar J, Hickey M, Gershlick A, Buszman P, Bochenek A, Schampaert E, Pag\u00e9 P, Dressler O, Kosmidou I, Mehran R, Pocock SJ, Kappetein AP, EXCEL Trail Investigators (2016) Everolimus-eluting stents or bypass surgery for left main coronary artery disease. N Engl J Med 375:2223\u20132235","journal-title":"N Engl J Med"},{"key":"1650_CR8","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1093\/eurheartj\/ehx512","volume":"38","author":"J Escaned","year":"2017","unstructured":"Escaned J, Collet C, Ryan N, De Maria GL, Walsh S, Sabate M, Davies J, Lesiak M, Moreno R, Cruz-Gonzalez I, Hoole SP, Ej West N, Piek JJ, Zaman A, Fath-Ordoubadi F, Stables RH, Appleby C, van Mieghem N, van Geuns RJ, Uren N, Zueco J, Buszman P, I\u00f1iguez A, Goicolea J, Hildick-Smith D, Ochala A, Dudek D, Hanratty C, Cavalcante R, Kappetein AP, Taggart DP, van Es GA, Morel MA, de Vries T, Onuma Y, Farooq V, Serruys PW, Banning AP (2017) Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II Study. Eur Heart J 38:3124\u20133134","journal-title":"Eur Heart J"},{"issue":"1100","key":"1650_CR9","first-page":"1109","volume":"39","author":"M Zeitouni","year":"2018","unstructured":"Zeitouni M, Silvain J, Guedeney P, Kerneis M, Yan Y, Overtchouk P, Barthelemy O, Hauguel-Moreau M, Choussat R, Helft G, Le Feuvre C, Collet JP, Montalescot G, ACTION Study Group (2018) Periprocedural myocardial infarction and injury in elective coronary stenting. Eur Heart J 39(1100):1109","journal-title":"Eur Heart J"},{"key":"1650_CR10","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJM199802193380807","volume":"338","author":"JD Parker","year":"1998","unstructured":"Parker JD, Parker JO (1998) Nitrate therapy for stable angina pectoris. N Engl J Med 338:520\u2013531","journal-title":"N Engl J Med"},{"key":"1650_CR11","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/S0140-6736(02)08265-X","volume":"359","author":"The IONA study group","year":"2002","unstructured":"The IONA study group (2002) Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomized trial. Lancet 359:1269\u20131275","journal-title":"Lancet"},{"key":"1650_CR12","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/S0735-1097(98)00604-4","volume":"33","author":"H Ito","year":"1999","unstructured":"Ito H, Taniyama Y, Iwakura K, Nishikawa N, Masuyama T, Kuzuya T, Hori M, Higashino Y, Fujii K, Minamino T (1999) Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol 33:654\u2013660","journal-title":"J Am Coll Cardiol"},{"key":"1650_CR13","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/FJC.0b013e3181b76730","volume":"54","author":"Y Minami","year":"2009","unstructured":"Minami Y, Nagashima M, Kajimoto K, Shiga T, Hagiwara N (2009) Acute efficacy and safety of intravenous administration of nicorandil in patients with acute heart failure syndromes: usefulness of noninvasive echocardiographic hemodynamic evaluation. J Cardiovasc Pharmacol 54:335\u2013340","journal-title":"J Cardiovasc Pharmacol"},{"key":"1650_CR14","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.jjcc.2010.06.009","volume":"56","author":"K Tanaka","year":"2010","unstructured":"Tanaka K, Kato K, Takano T, Katagiri T, Asanoi H, Nejima J, Nakashima M, Kamijo T, Sakanashi M (2010) Acute effects of intravenous nicorandil on hemodynamics in patients hospitalized with acute decompensated heart failure. J Cardiol 56:291\u2013299","journal-title":"J Cardiol"},{"key":"1650_CR15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/eurheartj\/eht463","volume":"35","author":"R Troughton","year":"2014","unstructured":"Troughton R, Michael Felker G, Januzzi JL Jr (2014) Natriuretic peptide-guided heart failure management. Eur Heart J 35:16\u201324","journal-title":"Eur Heart J"},{"key":"1650_CR16","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1161\/HYPERTENSIONAHA.116.08327","volume":"69","author":"A Pandey","year":"2017","unstructured":"Pandey A, Khan H, Newman AB, Lakatta EG, Forman DE, Butler J, Berry JD (2017) Arterial stiffness and risk of overall heart failure, heart failure with preserved ejection fraction, and heart failure with reduced ejection fraction: the Health ABC Study (health, aging, and body composition). Hypertension 69:267\u2013274","journal-title":"Hypertension"},{"key":"1650_CR17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.5551\/jat.13.101","volume":"13","author":"K Shirai","year":"2006","unstructured":"Shirai K, Utino J, Otsuka K, Takata M (2006) A novel blood pressure-independent arterial wall stiffness parameter: cardio-ankle vascular index (CAVI). J Atheroscler Thromb 13:101\u2013107","journal-title":"J Atheroscler Thromb"},{"key":"1650_CR18","doi-asserted-by":"publisher","first-page":"924","DOI":"10.5551\/jat.7716","volume":"18","author":"K Shirai","year":"2011","unstructured":"Shirai K, Hiruta N, Song M, Kurosu T, Suzuki J, Tomaru T, Miyashita Y, Saiki A, Takahashi M, Suzuki K, Takata M (2011) Cardio-ankle vascular index (CAVI) as a novel indicator of arterial stiffness: theory, evidence and perspectives. J Atheroscler Thromb 18:924\u2013938","journal-title":"J Atheroscler Thromb"},{"key":"1650_CR19","doi-asserted-by":"publisher","first-page":"49","DOI":"10.5551\/jat.3582","volume":"18","author":"K Shirai","year":"2011","unstructured":"Shirai K, Song M, Suzuki J, Kurosu T, Oyama T, Nagayama D, Miyashita Y, Yamamura S, Takahashi M (2011) Contradictory effects of \u03b21- and \u03b11-adrenergic receptor blockers on cardio-ankle vascular stiffness index (CAVI): CAVI is independent of blood pressure. J Atheroscler Thromb 18:49\u201355","journal-title":"J Atheroscler Thromb"},{"key":"1650_CR20","doi-asserted-by":"publisher","first-page":"479","DOI":"10.5551\/jat.9266","volume":"19","author":"M Takahashi","year":"2012","unstructured":"Takahashi M, Shiba T, Hirano K, Hitsumoto T, Shirai K (2012) Acute decrease of cardio-ankle vascular index with the administration of beraprost sodium. J Atheroscler Thromb 19:479\u2013484","journal-title":"J Atheroscler Thromb"},{"key":"1650_CR21","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2147\/VHRM.S106542","volume":"12","author":"K Shimizu","year":"2016","unstructured":"Shimizu K, Yamamoto T, Takahashi M, Sato S, Noike H, Shirai K (2016) Effect of nitroglycerin administration on cardio-ankle vascular index. Vasc Health Risk Manag 12:313\u2013319","journal-title":"Vasc Health Risk Manag"},{"key":"1650_CR22","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jphs.2015.07.002","volume":"128","author":"T Chiba","year":"2015","unstructured":"Chiba T, Yamanaka M, Takagi S, Shimizu K, Takahashi M, Shirai K, Takahara A (2015) Cardio-ankle vascular index (CAVI) differentiates pharmacological properties of vasodilators nicardipine and nitroglycerin in anesthetized rabbits. J Pharmacol Sci 128:185\u2013192","journal-title":"J Pharmacol Sci"},{"key":"1650_CR23","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s00259-013-2538-0","volume":"41","author":"S Kasama","year":"2014","unstructured":"Kasama S, Toyama T, Iwasaki T, Sumino H, Kumakura H, Minami K, Ichikawa S, Matsumoto N, Sato Y, Kurabayashi M (2014) Effects of oral nicorandil therapy on sympathetic nerve activity and cardiac events in patients with chronic heart failure: subanalysis of our previous report using propensity score matching. Eur J Nucl Med Mol Imaging 41:144\u2013154","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1650_CR24","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s00259-015-2990-0","volume":"42","author":"S Kasama","year":"2015","unstructured":"Kasama S, Toyama T, Funada R, Takama N, Koitabashi N, Ichikawa S, Suzuki Y, Matsumoto N, Sato Y, Kurabayashi M (2015) Effects of adding intravenous nicorandil to standard therapy on cardiac sympathetic nerve activity and myocyte dysfunction in patients with acute decompensated heart failure. Eur J Nucl Med Mol Imaging 42:761\u2013770","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Heart and Vessels"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-020-01650-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00380-020-01650-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-020-01650-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T23:40:31Z","timestamp":1624318831000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00380-020-01650-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,22]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1650"],"URL":"https:\/\/doi.org\/10.1007\/s00380-020-01650-9","relation":{},"ISSN":["0910-8327","1615-2573"],"issn-type":[{"value":"0910-8327","type":"print"},{"value":"1615-2573","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,22]]},"assertion":[{"value":"13 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the ethics committee of Toho University Medical Center Sakura Hospital (S17058) and performed in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Informed consent was obtained from all patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}